Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%). J of Skin 2024, 8 (6), s421. https://doi.org/10.25251/skin.8.supp.421.